Equal Access to Cancer Care Helps Close Racial Survival Gap

According to a study out of St. Jude Children's Hospital's Department of Oncology and published in the Journal of Clinical Oncology, equal access to good cancer care for blacks and whites translates into equal survival rates and long-term cancer survivors.

Traditionally, African-Americans of all ages have been on the wrong end of disparities in cancer survivorship, being less likely than their white counterparts to beat cancer and become cancer survivors.

However, the work being done at St. Jude's, where children are treated regardless of their ability to pay for the treatment, researchers have seen a closing of the survival gap between the races. In a 15 year period beginning in 1992 and ending in 2007 at all treatment centers, patient outcomes were improved in African Americans in particular in those with acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma, but the gap worsened for patients with acute myeloid leukemia (AML) and neuroblastoma.

However, at St. Jude's, survival gains were the same for virtually all cancers examined in this study (19), demonstrating that when given access to equal care, race is not a barrier to cancer outcomes.

According to Dr. William E. Evans, St. Jude CEO and co-author of the study, "These findings flow directly from Danny Thomas' strong view that to conquer childhood cancer, treatment must be equally available across all racial and ethnic groups, which has been the case at St. Jude since he opened the doors in 1962."

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap